World Investment Advisors Purchases 16,749 Shares of DexCom, Inc. $DXCM

World Investment Advisors grew its position in DexCom, Inc. (NASDAQ:DXCM) by 34.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 65,089 shares of the medical device company’s stock after buying an additional 16,749 shares during the quarter. World Investment Advisors’ holdings in DexCom were worth $4,320,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Reflection Asset Management bought a new position in shares of DexCom in the fourth quarter valued at approximately $25,000. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. MCF Advisors LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $32,000. ORG Partners LLC raised its stake in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Finally, DV Equities LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $36,000. Institutional investors own 97.75% of the company’s stock.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

DexCom Stock Performance

Shares of DexCom stock opened at $72.86 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market cap of $28.11 billion, a P/E ratio of 31.14, a P/E/G ratio of 1.14 and a beta of 1.45. The firm has a 50 day simple moving average of $64.83 and a 200 day simple moving average of $66.98. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the previous year, the business earned $0.32 EPS. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. Sell-side analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at approximately $6,560,384.64. The trade was a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the sale, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 42,694 shares of company stock worth $3,029,267 over the last quarter. 0.28% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Mizuho set a $75.00 price target on shares of DexCom in a report on Friday, May 1st. William Blair raised shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. Truist Financial reissued a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, March 24th. Finally, Benchmark assumed coverage on shares of DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.63.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.